동물용 항생제 시장 규모, 점유율, 동향 분석 리포트 : 동물 유형별, 약제 클래스별, 제형별, 지역별, 부문별 예측(2025-2030년)

Veterinary Antibiotics Market Growth & Trends:

The global veterinary antibiotics market size is expected to reach USD 5.91 billion in 2030 and is anticipated to grow at a CAGR of 2.54% from 2025 to 2030. The primary drivers of market growth include a rising focus on animal-only antibiotics and ionophores, growing initiatives by key companies and the launch of new products, and the increasing incidence of livestock diseases. Key players are significantly launching new antibiotics to meet the demand, as some of the older antibiotics have been associated with resistance. For instance, in January 2023, Norbrook launched Tulieve, a generic tulathromycin injection for treating bacterial infections in beef cattle, nonlactating dairy cattle, and swine.

Similarly, in December 2021, Virbac launched Tulissin, an antibiotic solution for swine and cattle with respiratory pathologies. These products were made available for European veterinarians. Therefore, R&D and manufacturing for antibiotic development are ongoing, which is anticipated to continue without a complete halt anytime soon. This factor is contributing to the market growth.

One of the opportunities to further accelerate market growth in the future is the discovery of novel antibiotics. There is a continuous need for new antibiotics to combat emerging resistant strains in veterinary medicine. Research and development in this area could lead to breakthrough drugs that address unmet needs in treating animal infections. According to the U.S. Department of Agriculture, the development of innovative drugs could reduce resistance and the need for existing antibiotics in the production of food animals. Moreover, the need for medications intended for companion animals may promote the development of novel products for that market rather than for use in food animals. On the other hand, increasing export demand for U.S. meat is intensifying animal illness challenges caused by globalization, and the development of antibiotic resistance in animals could boost the demand for antibiotics and the development of new antibiotics.

Moreover, major veterinary antibiotic manufacturers are facing severe competition from generic drug developers globally. These generic products also create pricing pressure on manufacturers owing to their cost-effectiveness. As the patent for antibiotic products expires, generic drug developers introduce alternative forms of products into the market. For instance, Elanco's Maxiban (an ionophore/animal-only antibiotic) has no patent protection as of 2021, thus, competitors might begin to develop generic & lower-priced alternatives. Similarly, Zoetis reported in 2021 that the company faces competition from generic product developers once a product's patent expires. As a result, the company has been compelled to reduce its prices and provide discounts for major products to compete with the lower-priced alternative generic products available in the market. Therefore, increasing generic competition is expected to create challenges in the market in the long run.

In addition, the rising awareness of livestock diseases is predicted to create a demand for veterinary treatment in hospitals & clinics, creating a requirement for veterinary antibiotics. For instance, Ontario has approximately 5,247 veterinarians, followed by 1,650 in British Columbia. Furthermore, antibiotics used for livestock treatment must meet Health Canada's human & animal safety standards. Veterinarians can choose from various antibiotics designed to help prevent or lower the severity of diseases that threaten animals. Every antibiotic marketed in the country must be licensed by the Canadian Food Inspection Agency. Such factors are likely to propel market growth.

Veterinary Antibiotics Market Report Highlights:

• Based on animal type, the cattle segment held the dominant market share of 39.69% in 2024. Increased consumption of beef and dairy products is a major factor expected to drive the segment.
• Based on drug class,the tetracyclines segment dominated the veterinary antibiotics market in 2024 with a share of 29.04%. Tetracyclines are a class of commonly used veterinary antibiotics.
• The oral solutions segment dominated the market in 2024. Oral liquids or solutions are among the easiest dosage forms of veterinary antibiotics to develop and use.
• The veterinary antibiotics market in North America accounted for the largest revenue share of 32.37% in 2024. This regional market is likely to be driven by the presence of established players and increasing demand for treatment among veterinary practices.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Antibiotics Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising focus on animal-only antibiotics and ionophores
    • 3.2.1.2. Growing Initiatives by key companies And launch of new products
    • 3.2.1.3. Increasing Incidence of Livestock Diseases
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent regulations
    • 3.2.2.2. Decline In the use of antibiotics
    • 3.2.2.3. Rising research on antibiotic alternatives
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Veterinary Antibiotics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Patent-Off Dates Analysis for Major Veterinary Antibiotics
  • 3.3.5. Product Pipeline Analysis
  • 3.3.6. Overall Estimated Sales Of Antimicrobial VMPs (Active Substance) In Tonnes By European Country, 2023
  • 3.3.7. Estimated Sales Of Antimicrobial Active Substances in Production Animals in Europe, By Antimicrobial Class, 2023
  • 3.3.8. COVID-19 Impact Analysis

Chapter 4. Veterinary Antibiotics Market: Animal Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Veterinary Antibiotics Market: Animal Type Movement Analysis
• 4.3. Veterinary Antibiotics Market Size & Trend Analysis, by animal type, 2018 to 2030 (USD Million)
• 4.4. Cattle
  • 4.4.1. Cattle Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Pigs
  • 4.5.1. Pigs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Sheep & Goat
  • 4.6.1. Sheep & Goat Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Poultry
  • 4.7.1. Poultry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Veterinary Antibiotics Market: Drug Class Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Veterinary Antibiotics Market: By Drug Class Movement Analysis
• 5.3. Veterinary Antibiotics Market Size & Trend Analysis, by drug class, 2018 to 2030 (USD Million)
  • 5.3.1. Tetracyclines
    • 5.3.1.1. Tetracyclines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Penicillins
    • 5.3.2.1. Penicillins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Sulfonamides
    • 5.3.3.1. Sulfonamides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Penicillins
    • 5.3.4.1. Penicillins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.5. Macrolides
    • 5.3.5.1. Macrolides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.6. Trimethoprim
    • 5.3.6.1. Trimethoprim Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.7. Lincosamides
    • 5.3.7.1. Lincosamides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.8. Polymyxins
    • 5.3.8.1. Polymyxins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.9. Aminoglycosides
    • 5.3.9.1. Aminoglycosides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.10. Fluoroquinolones
    • 5.3.10.1. Fluoroquinolones Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.11. Pleuromutilins
    • 5.3.11.1. Pleuromutilins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.12. Others
    • 5.3.12.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Veterinary Antibiotics Market: Dosage Form Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Veterinary Antibiotics Market: By Dosage Form Movement Analysis
• 6.3. Veterinary Antibiotics Market Size & Trend Analysis, by dosage form, 2018 to 2030 (USD Million)
  • 6.3.1. Oral Powders
    • 6.3.1.1. Oral Powders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Oral solutions
    • 6.3.2.1. Oral Solutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Injections
    • 6.3.3.1. Injections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. Others
    • 6.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Veterinary Antibiotics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Veterinary Antibiotics Market Share, By Region, 2024 & 2030, USD Million
• 7.3. Regional Outlook
• 7.4. North America
  • 7.4.1. North America Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. U.S. Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Canada Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. UK Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Germany Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. France Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Italy Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Spain Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Denmark Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Sweden Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Norway Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.10. Belgium
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Belgium Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.11. Hungary
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Hungary Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.12. Poland
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Poland Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.13. Portugal
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Portugal Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.14. Romania
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Romania Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.15. Netherlands
    • 7.5.15.1. Key Country Dynamics
    • 7.5.15.2. Romania Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Japan Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. China Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. India Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Australia Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. South Korea Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Brazil Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Mexico
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Mexico Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. Argentina
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Argentina Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. South Africa Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Saudi Arabia Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. UAE Veterinary Antibiotics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Position Analysis/ Heap Map Analysis
• 8.3. Company Profiles
  • 8.3.1. Merck & Co., Inc.
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Ceva Sante Animale.
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Vetoquinol
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Zoetis Services LLC
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Boehringer Ingelheim International GmbH
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Dechra Pharmaceuticals PLC
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Elanco Animal Health Incorporated
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Virbac S.A.
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Calier.
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Bimeda, Inc
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Prodivet Pharmaceuticals SA/NV
    • 8.3.11.1. Participant's Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Product Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Norbrook Laboratories
    • 8.3.12.1. Participant's Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Product Benchmarking
    • 8.3.12.4. Strategic Initiatives
• 8.4. Strategy Mapping
  • 8.4.1. Mergers & Acquisitions
  • 8.4.2. Partnerships & Collaborations
  • 8.4.3. Expansion
  • 8.4.4. Product launch
  • 8.4.5. Product Approval
  • 8.4.6. Others
• 8.5. List of Other Players